VSTM trades 217.5% below Wall Street's consensus target of $15.40.
Last 12 months price action with 12-month analyst target path
The base valuation assumes VSTM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 19 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Verastem, Inc. (VSTM) has a Wall Street consensus price target of $15.40, based on estimates from 19 covering analysts. With the stock currently trading at $4.85, this represents a potential upside of +217.5%. The company has a market capitalization of $336M.
Analyst price targets range from a low of $8.00 to a high of $18.00, representing a 65% spread in expectations. The median target of $18.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, VSTM trades at a trailing P/E of -1.6x. Analysts expect EPS to grow +20.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
KPTIKaryopharm Therapeutics Inc. | $86M | $10.05 | $14.17 | +41.0% | Buy | — | 20 |
MGNXMacroGenics, Inc. | $302M | $4.75 | $6.00 | +26.3% | Buy | — | 22 |
TGTXTG Therapeutics, Inc. | $8.2B | $53.52 | $64.00 | +19.6% | Buy | 39.4x | 13 |
IMVTImmunovant, Inc. | $8.2B | $40.09 | $45.00 | +12.2% | Buy | — | 23 |
PRMEPrime Medicine, Inc. | $721M | $3.99 | $7.00 | +75.4% | Buy | — | 9 |
AGENAgenus Inc. | $146M | $3.50 | $7.33 | +109.4% | Buy | 4.5x | 11 |
IDYAIDEAYA Biosciences, Inc. | $3.6B | $40.51 | $58.67 | +44.8% | Buy | — | 25 |
RCUSArcus Biosciences, Inc. | $3.0B | $30.25 | $31.00 | +2.5% | Buy | — | 18 |
NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
PTCTPTC Therapeutics, Inc. | $7.4B | $89.20 | $95.83 | +7.4% | Buy | 100.7x | 26 |
Quick answers to the most common questions about buying VSTM stock.
The consensus Wall Street price target for VSTM is $15.4, representing 217.5% upside from the current price of $4.85. With 19 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
VSTM has a consensus rating of "Buy" based on 19 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $15.4 implies 217.5% upside from current levels.
VSTM's current price is $4.85 with a consensus target of $15.4 (217.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $18 for VSTM, while the most conservative target is $8. The consensus of $15.4 represents the median expectation. These targets typically reflect 12-month expectations.
VSTM is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month VSTM stock forecast based on 19 Wall Street analysts shows a consensus price target of $15.4, with estimates ranging from $8 (bear case) to $18 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on VSTM, with a "Buy" consensus rating and $15.4 price target (217.5% upside). 15 of 19 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
VSTM analyst price targets range from $8 to $18, a 65% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15.4 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.